Precision medicine: In need of guidance and surveillance
- PMID: 28811702
- PMCID: PMC5537174
- DOI: 10.3748/wjg.v23.i28.5045
Precision medicine: In need of guidance and surveillance
Abstract
Precision medicine, currently a hotspot in mainstream medicine, has been strongly promoted in recent years. With rapid technological development, such as next-generation sequencing, and fierce competition in molecular targeted drug exploitation, precision medicine represents an advance in science and technology; it also fulfills needs in public health care. The clinical translation and application of precision medicine - especially in the prevention and treatment of tumors - is far from satisfactory; however, the aims of precision medicine deserve approval. Thus, this medical approach is currently in its infancy; it has promising prospects, but it needs to overcome numbers of problems and deficiencies. It is expected that in addition to conventional symptoms and signs, precision medicine will define disease in terms of the underlying molecular characteristics and other environmental susceptibility factors. Those expectations should be realized by constructing a novel data network, integrating clinical data from individual patients and personal genomic background with existing research on the molecular makeup of diseases. In addition, multi-omics analysis and multi-discipline collaboration will become crucial elements in precision medicine. Precision medicine deserves strong support, and its development demands directed momentum. We propose three kinds of impetus (research, application and collaboration impetus) for such directed momentum toward promoting precision medicine and accelerating its clinical translation and application.
Keywords: Clinical translation; Development; Immunotherapy; Precision medicine; Targeted therapy.
Conflict of interest statement
Conflict-of-interest statement: All the authors declare no conflict of interest related to this publication and approve the final version of the manuscript.
References
-
- Tannock IF, Hickman JA. Limits to Personalized Cancer Medicine. N Engl J Med. 2016;375:1289–1294. - PubMed
-
- Prasad V. Perspective: The precision-oncology illusion. Nature. 2016;537:S63. - PubMed
-
- Le Tourneau C, Delord JP, Gonçalves A, Gavoille C, Dubot C, Isambert N, Campone M, Trédan O, Massiani MA, Mauborgne C, et al. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. Lancet Oncol. 2015;16:1324–1334. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources